Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia

Table 2 Summary of patient demographic and disease characteristics as well as treatment outcomes in 187 CML patients treated with imatinib

Characteristics	Variables	No of pts (%)
Gender	Female	79 (42)
Gender	Male	109 (58)
Age	(Years, median, range)	49.0 (11–87)
Follow-up duration	(Months, median, range)	41.7 (0–98.1)
Cytogenetics at diagnosis	t(9;22) only	153 (81)
	Additional abnormalities^*	27 (15)
	Unknown	7 (4)
Sokal risk group at diagnosis	Low	59 (32)
	Intermediate	69 (37)
	High	42 (22)
	Unknown	17 (9)
Disease stage at imatinib therapy	CP	169 (90)
	AP	11 (6)
	BC	7 (4)
Previous treatment (any)	De novo	145 (77.5)
Previous treatment (any)	Previously treated	42 (22.5)
Previous treatment prior to imatinib	Interferon-alpha	30 (16.0)
Duration of imatinib therapy	Median in months (range)	36.9 (0–98.1)

AP accelerated phase, BC blastic crisis, CP chronic phase
* Additional cytogenetic abnormalities: t(9; 22; 11) (n = 1); t(7; 9; 22) (n = 1); t(9; 22; 17) (n = 1); t(9; 22; 19) (n = 1); t(4; 22) with t(17; 20) (n = 1); inv(3) (n = 2); der(9) (n = 1); der(9), del(9) (n = 1); del(22q) (n = 1); +der(22) (n = 3); −Y(n = 1); +8(n = 1); −12 (n = 1); 92, idemx2(n = 3); 69, XXX with 92, XXXX and 138, XXXXXX (n = 1), t(8;9;22) (n = 1); dup(1) (n = 1)

ISSN: 1479-5876